Skip to main content
Signal8

VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update

$VNRXPress releaseNov 12, 2026, 4:10 PM ETRead the release

VolitionRx reported Q3 2026 revenue of approximately $1.6 million, up 157% year-over-year from $0.6 million, driven by increased recognition of deferred revenue. Losses narrowed materially: operating loss fell 35% to $3.3 million and net loss to $3.8 million, aided by 14% lower operating expenses and a 28% headcount reduction. The company also prepaid its $7.5 million convertible note in cash. Cash stands at only $2.4 million despite $5.2 million of ATM proceeds in the quarter, and the CEO took a further salary cut to 50% of original level while the board cut cash fees at least 50%, underlining funding pressure pending a substantial licensing deal.

Key figures

Revenue
$1.6 million
Revenue Yoy
157%
Cash
$2.4 million
Net loss
$3.8 million
Operating loss
$3.3 million
Opex change yoy
-14%
Atm net proceeds
$5.2 million
Cash prior year end
$1.1 million
Ceo base salary cut
50%
Headcount reduction
28%
Net loss prior year
$5.4 million
Detecseps program value
€6.3 million
Convertible note prepaid
$7.5 million
Feline assay sensitivity
86%
Feline assay specificity
97%
Operating loss prior year
$5.1 million
Mced mrd addressable market
$36 billion
Feline lymphoma milestone payment
$5 million

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    VNRX: VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update — AI Analysis | Signal8